Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis

Background The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may benefit from an increase in dosing frequency to 40 mg every week (EW). Objective To deter...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2018-08, Vol.32 (8), p.1297-1304
Main Authors: Gniadecki, R., Leonardi, C.L., Gordon, K.B., Gu, Y., Geng, Z., Nader, A., Teixeira, H.D.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may benefit from an increase in dosing frequency to 40 mg every week (EW). Objective To determine the long‐term efficacy of adalimumab in patients with psoriasis with flexibility to escalate and de‐escalate between EOW and EW dosing. Methods Data from an open‐label study in patients with psoriasis who had received adalimumab in phase 2/3 studies and their extensions were included. Patients initially received 40 mg adalimumab EOW for 24 weeks. From weeks 24–252, patients whose Psoriasis Area and Severity Index response was
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.14926